The goal of this observational study is to compare glycemic control and irisin levels in subjects with diabetes mellitus type 2 with sarcopenic obesity vs non-sarcopenic obesity.
The main questions it aims to answer are:
Is glycemic control worse in diabetic patients with sarcopenic obesity? Are irisin levels higher in patients with non-sarcopenic obesity?
Participants will be asked to:
* Fill in three questionaries on lifestyle * Perform two physical performance tests
The investigators will collect the following data:
* Anthropometric measurements * Body composition by bioelectrical impedance analysis. * Results of routine blood analyses * Irisin levels by drawing a vial of blood from the antecubital vein
Diabetes mellitus type 2 diagnosed less than 10 years before
age >60 years
BMI (Body Mass Index) >30 kg/m2
eGFR (estimated Glomerular Filtration Rate) >30 ml/min
Insulin or insulin secretagogues use
Diabetes mellitus type 1, previous diabetic ketoacidosis
Neuromuscular diseases
Endocrinopathies that may cause myopathies (hypercortisolism, GH [growth hormone] deficiency, acromegaly, adrenal insufficiency, partial hypopituitarism or panhypopituitarism, male hypogonadism, hyperparathyroidism, hypoparathyroidism)
Patients will be selected from our Center's patients. A physician will screen the eligible patients from the automatic search on the database from the program Smart Digital Clinic.
Case-control
Other
Not listed
Differences in glycated hemoglobin and/or insulin resistance in diabetic patients with non-sarcopenic obesity vs patients with sarcopenic obesity
Differences in glycated hemoglobin or in HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) in patients with sarcopenic obesity vs non-sarcopenic obesity
Click on the lead sponsor to view all of their trials.
